PASG, US7027122099

Passage Bio outlines USD 100.0 million financing for Passage Bio stock

Published on 10/16/2026 at 04:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Passage Bio outlines USD 100.0 million merger financing. Passage Bio stock faces a November 5 vote and a 6.00 percent ownership share.

Merger financing and approval date

The October 9, 2026 prospectus projects USD 100.0 million in merger financing.
Passage Bio holders are projected to own 6.00 percent after the transaction.
Stockholders are scheduled to vote on the merger on November 5, 2026.

PASG, US7027122099, Illustration mit AI erstellt.

Passage Bio (ISIN US7027122099) outlined expected gross proceeds of USD 100.0 million from financing linked to its proposed merger with Remix Therapeutics in a prospectus dated October 9, 2026, according to StockTitan. Passage Bio stockholders are scheduled to vote on the transaction on November 5, 2026.

Financing sets the transaction scale

The filing describes USD 70.0 million of common-stock and pre-funded-warrant sales alongside USD 30.0 million of convertible notes. The financing must deliver at least USD 99.929 million in cash proceeds unless the parties waive that condition, making funding a central closing test.

The proposed transaction would combine Passage Bio with Remix through two merger steps. Passage Bio would change its name to Remix Therapeutics, Inc., while the combined company is expected to trade on Nasdaq under the symbol RMTX after closing, subject to approvals and other conditions.

What does ownership mean?

Under the assumptions in the October 9 filing, pre-merger Remix holders would own 65.00 percent of the combined company, financing investors 29.00 percent and existing Passage Bio holders 6.00 percent. The figures are calculated on a fully diluted basis and can change with final cash and capitalization.

Three filing dates mark the path

On June 24, 2026, Passage Bio and Remix entered their original merger agreement. On September 2, 2026, they amended and restated the agreement while setting a USD 70.0 million subscription financing. On October 5, 2026, Passage Bio filed a further amendment covering the USD 100.0 million financing structure and the planned November vote, according to StockTitan.

Approval comes before closing

The next stated date is November 5, 2026, when Passage Bio stockholders are scheduled to vote on the stock issuance, reverse split and charter proposals. The proposed reverse split has a range of 1-for-2 to 1-for-10, and the merger is expected to close in the fourth quarter of 2026 if the required conditions are met.

Passage Bio remains a biotechnology issuer

Passage Bio is a healthcare biotechnology company developing genetic medicines for neurodegenerative diseases. Its shares are listed on Nasdaq under PASG, while the proposed transaction would move the combined company to the RMTX symbol after completion.